XML 79 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215
Cost of product revenue 2,249 9,786 9,947 29,577
Research and development 13,662 21,821 47,651 60,410
Selling, general and administrative 12,302 13,499 41,066 39,859
Restructuring charges 3,140 0 3,284 0
Asset impairment and other charges 9,984 0 9,984 0
Total costs and operating expenses 41,337 45,106 111,932 129,846
Loss from operations (32,060) (10,636) (68,350) (21,631)
Loss before income taxes (34,899) (9,984) (69,014) (20,863)
Goodwill impairment 800   778  
Stock-based compensation 2,283 4,531 7,808 11,600
Performance Enzymes        
Segment Reporting Information [Line Items]        
Goodwill impairment     0  
Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Goodwill impairment     778  
Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 5,395 28,042 24,807 93,376
Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 3,882 6,428 18,775 14,839
Operating segments        
Segment Reporting Information [Line Items]        
Total revenues 9,277 34,470 43,582 108,215
Cost of product revenue 2,249 9,786 9,947 29,577
Research and development 12,523 20,637 44,029 57,112
Selling, general and administrative 2,134 4,679 8,106 13,496
Restructuring charges 2,399 0 2,544 0
Asset impairment and other charges 778 0 778 0
Total costs and operating expenses 20,083 35,102 65,404 100,185
Loss from operations (10,806) (632) (21,822) 8,030
Stock-based compensation 2,283 4,531    
Operating segments | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 8,710 31,146 37,503 100,774
Cost of product revenue 2,249 9,786 9,947 29,577
Research and development 8,146 6,782 24,100 19,833
Selling, general and administrative 1,748 3,791 6,578 11,208
Restructuring charges 1,182 0 1,182 0
Asset impairment and other charges 0 0 0 0
Total costs and operating expenses 13,325 20,359 41,807 60,618
Loss from operations (4,615) 10,787 (4,304) 40,156
Stock-based compensation 903 1,593 2,861 4,776
Operating segments | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 567 3,324 6,079 7,441
Cost of product revenue 0 0 0 0
Research and development 4,377 13,855 19,929 37,279
Selling, general and administrative 386 888 1,528 2,288
Restructuring charges 1,217 0 1,362 0
Asset impairment and other charges 778 0 778 0
Total costs and operating expenses 6,758 14,743 23,597 39,567
Loss from operations (6,191) (11,419) (17,518) (32,126)
Stock-based compensation (235) 414 98 1,182
Operating segments | Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 5,395 28,042 24,807 93,376
Operating segments | Product revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 5,395 28,042 24,807 93,376
Operating segments | Product revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 0 0 0 0
Operating segments | Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 3,882 6,428 18,775 14,839
Operating segments | Research and development revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 3,315 3,104 12,696 7,398
Operating segments | Research and development revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 567 3,324 6,079 7,441
Corporate, non-segment        
Segment Reporting Information [Line Items]        
Total costs and operating expenses (22,736) (7,947) (42,890) (24,940)
Unallocated depreciation and amortization (1,357) (1,405) (4,302) (3,953)
Stock-based compensation $ 1,615 $ 2,524 $ 4,849 $ 5,642